Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vaginal Heat Wash-Out Device · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Vaginal Heat Wash-Out Device | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Vaginal Heat Wash-Out Device | DEVICE | No drug administered. Device tested three times with each subject. |
Inclusion Criteria: * Pre-menopausal healthy women aged 18-45 with regular, natural menstrual cycles. * Subjects must be void of Female Sexual Disorder. Exclusion Criteria: * Pregnant or lactating women * Postmenopausal subjects * Subjects with evidence or history of clinically significant hemato...
The Vaginal Heat Wash-Out Device is an investigational device being studied for sexual dysfunction, physiological, in women. It is in Phase 1 clinical development and is not yet approved. Two early-stage trials have been completed to evaluate its effects on vaginal blood flow and its use in pre- and postmenopausal women with and without female sexual arousal disorder.
Pfizer, Inc. (NYSE: PFE) is developing the Vaginal Heat Wash-Out Device. The company is conducting Phase 1 clinical trials to evaluate the device in women with physiological sexual dysfunction. The device is still in early-stage clinical development and is not yet approved for commercial use.
The Vaginal Heat Wash-Out Device is in Phase 1 clinical development. Two Phase 1 trials have been completed, with a total of 76 participants enrolled. The device is investigational and has not received regulatory approval. It is being studied for physiological sexual dysfunction in women.
The Vaginal Heat Wash-Out Device has been studied in two completed Phase 1 trials: NCT00443027, which examined the effect of the menstrual cycle on vaginal blood flow in pre-menopausal healthy women, and NCT00443248, which evaluated the device in pre- and postmenopausal women with and without female sexual arousal disorder. Both trials were conducted in Australia.
The Vaginal Heat Wash-Out Device is not FDA approved. It is an investigational device currently in Phase 1 clinical development. Two early-stage trials have been completed, but the device has not yet been evaluated in later-phase studies or submitted for regulatory approval. It remains under investigation for physiological sexual dysfunction.